Targeting and Modulating CRAC Channels to Treat Acute Pancreatitis and COVID-19 with Dr. Sudarshan Hebbar CalciMedica

Dr. Sudarshan Hebbar, Chief Medical Officer, CalciMedica talks about developing drugs that are focused on targeting CRAC channels, calcium release activated calcium channels, in order to modulate these channels to help treat diseases that have a significant inflammatory component.  Initially developed drugs for acute pancreatitis targeting both the pancreas and the lung. Now conducting large trial in patients with severe and critical COVID-19 as many of the mechanisms that are shared in the development of lung disease with COVID-19 are shared with acute pancreatitis. Strong evidence that their drug Auxora  might be effective for a variety of disorders that cause lung injury.

@CalciMedicaInc #COVID19 #CriticalCare #inflammatorydiseases #pancreatitis #CRACChannelinhibitors

Download the transcript here

Share on facebook
Share on twitter
Share on linkedin
Related Post


Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.